GILBERTO DE CASTRO JUNIOR
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
conferenceObject Treatment with sorafenib in progressive metastatic medullary thyroid cancer (MTC) is well tolerated and is associated with symptom and tumor control(2014) PAPADIA, C. M.; CASTRONEVES, L. A.; FREITAS, R.; LOURENCO, D. M.; CASTRO JR., G. de; TAVARES, M. R.; HOFF, A. O.conferenceObject Reversal of T3 Thyrotoxicosis By Lenvatinib in Metastatic Follicular Thyroid Carcinoma: Report of 2 Cases(2014) HOFF, Ana O.; DANILOVIC, Debora Seguro; CASTRO, Gilberto; PAPADIA, Carla; MARUI, Suemi; CAMARGO, Rosalinda- Meta-Analysis of First-Line Therapies in Advanced Non-Small-Cell Lung Cancer Harboring EGFR-Activating Mutations(2014) HAALAND, Benjamin; TAN, Pui San; CASTRO JR., Gilberto de; LOPES, GilbertoIntroduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared with chemotherapy as first-line therapies for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor-activating mutations. This meta-analysis compares gefitinib, erlotinib, afatinib, and chemotherapy. Methods: Literature search was performed using relevant keywords. Direct and indirect meta-estimates were generated using log-linear mixed-effects models, with random effects for study. Study-to-study heterogeneity was summarized using I-2 statistics and predictive intervals (PIs). Results: Literature search yielded eight randomized phase 3 clinical trials comparing gefitinib, erlotinib, or afatinib with chemotherapy as first-line therapy in patients with advanced non-small-cell lung cancer during the last 5 years. Hazard ratio meta-estimates for progression-free survival were for gefitinib versus chemotherapy 0.44 (95% confidence interval [CI] 0.31-0.63; 95% PI, 0.22-0.88), erlotinib versus chemotherapy 0.25 (95% CI, 0.15-0.42; 95% PI, 0.11-0.55), afatinib versus chemotherapy 0.44 (95% CI, 0.26-0.75; 95% PI, 0.20-0.98), erlotinib versus gefitinib 0.57 (95% CI, 0.30-1.08; 95% PI, 0.24-1.36), afatinib versus gefitinib 1.01 (95% CI, 0.53-1.92; 95% PI, 0.41-2.42), and erlotinib versus afatinib 0.56 (95% CI, 0.27-1.18; 95% PI, 0.22-1.46). Results for overall response rate and disease control rate were similar. There was no evidence that gefitinib, erlotinib, or afatinib improved overall survival compared with chemotherapy. Conclusion: Gefitinib, erlotinib, and afatinib out-performed chemotherapy in terms of progression-free survival, overall response rate, and disease control rate. Differences among gefitinib, erlotinib, and afatinib were not statistically significant.
- Economic Analyses in Squamous Cell Carcinoma of the Head and Neck: A Review of the Literature From a Clinical Perspective(2014) SOUZA, Jonas A. de; SANTANA, Iuri A.; CASTRO JR., Gilberto de; LOPES JR., Gilberto de Lima; SHIH, Ya-Chen TinaThe purpose of this review was to describe cost-effectiveness and cost analysis studies across treatment modalities for squamous cell carcinoma of the head and neck (SCCHN), while placing their results in context of the current clinical practice. We performed a literature search in PubMed for English-language studies addressing economic analyses of treatment modalities for SCCHN published from January 2000 to March 2013. We also performed an additional search for related studies published by the National Institute for Health and Clinical Excellence in the United Kingdom. Identified articles were classified into 3 clinical approaches (organ preservation, radiation therapy modalities, and chemotherapy regimens) and into 2 types of economic studies (cost analysis and cost-effectiveness/cost-utility studies). All cost estimates were normalized to US dollars, year 2013 values. Our search yielded 23 articles: 13 related to organ preservation approaches, 5 to radiation therapy modalities, and 5 to chemotherapy regimens. In general, studies analyzed different questions and modalities, making it difficult to reach a conclusion. Even when restricted to comparisons of modalities within the same clinical approach, studies often yielded conflicting findings. The heterogeneity across economic studies of SCCHN should be carefully understood in light of the modeling assumptions and limitations of each study and placed in context with relevant settings of clinical practices and study perspectives. Furthermore, the scarcity of comparative effectiveness and quality-of-life data poses unique challenges for conducting economic analyses for a resource-intensive disease, such as SCCHN, that requires a multimodal care. Future research is needed to better understand how to compare the costs and cost-effectiveness of different modalities for SCCHN. (C) 2014 Elsevier Inc.
- Micromorphology of the Dental Pulp Is Highly Preserved in Cancer Patients Who Underwent Head and Neck Radiotherapy(2014) FARIA, Karma Morais; BRANDAO, Thais Bianca; RIBEIRO, Ana Carolina Prado; VASCONCELLOS, Adriele Ferreira Gouvea; CARVALHO, Icaro Thiago de; ARRUDA, Fernando Freire de; CASTRO JUNIOR, Gilberto; GROSS, Vanessa Cristina; ALMEIDA, Oslei Paes; LOPES, Marcio Ajudarte; SANTOS-SILVA, Alan RogerIntroduction: Teeth are often included in the radiation field during head and neck radiotherapy, and recent clinical evidence suggests that dental pulp is negatively affected by the direct effects of radiation, leading to impaired sensitivity of the dental pulp: Therefore, this study aimed to investigate the direct effects of radiation on the microvasculature, innervation, and extracellular matrix of the dental pulp of patients who have undergone head and neck radiotherapy. Methods: Twenty-three samples of dental pulp from patients who finished head and neck radiotherapy were analyzed. Samples were histologically processed and stained with hematoxylin-eosin for morphologic evaluation of the microvasculature, innervation, and extracellular matrix. Subsequently, immunohistochemical analysis of proteins related to vascularization (CD34 and smooth muscle actin), innervation (S-100, NCAM/CD56, and neurofilament), and extracellular matrix (vimentin) of the dental pulp was performed. Results: The morphologic study identified preservation of the microvasculature, nerve bundles, and components of the extracellular matrix in all studied samples. The immunohistochemical analysis confirmed the morphologic findings and showed a normal pattern of expression for the studied proteins in all samples. Conclusions: Direct effects of radiotherapy are not able to generate morphologic changes in the microvasculature, innervation, and extracellular matrix components of the dental pulp in head and neck cancer patients.
conferenceObject Sorafenib Treatment Improves Refractory Hypercalcemia in a Patient with Metastatic Parathyroid Carcinoma: A Case Report(2014) LERARIO, Antonio M.; MARTIN, Regina M.; HOFF, Ana Oliveira; NAKAGUMA, Marilena; CASTRO, Gilberto; TEIXEIRA, Carlos Henrique; MENEZES, Marcos; DALALIO, Vanessa; MENDONCA, Berenice B.conferenceObject Maintenance chemotherapy (MC) in advanced non-small cell Jung cancer (NSCLC): A meta-analysis.(2014) CASTRIA, Tiago Biachi De; CASTRO, Gilberto; HOFF, Paulo MarceloconferenceObject Chemoradiation with or without nimotuzumab in locally advanced esophageal cancer (LAEC): A randomized phase II study (NICE trial).(2014) CASTRO, Gilberto; SKARE, Nils G.; ANDRADE, Carlos J. C.; SEGALLA, J. G. M.; AZEVEDO, Sergio Jobim De; SILVA, Ismael D. C. G.; MALUF FILHO, Fauze; NEUSQUEN, Lucienne Pereira Del Grossi; BERTO, Cassiano Ricardo de OliveiraconferenceObject SURGICAL AND CLINICAL TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA: RETROSPECTIVE ANALYSIS OF 15 YEARS(2014) TERRA, Ricardo Mingarini; BIBAS, Benoit Jacques; COSTA, Priscila Berenice; TAMAGNO, Mauro Federico Luis; TAKAGAKI, Teresa Yae; BEYRUTI, Ricardo; CASTRO JR., Gilberto De; PEGO-FERNANDES, PaulobookPart Timoma e Carcinoma Tímico(2014) KATZ, Artur; MARQUES, Ricardo; CASTRO, Gilberto de; MEDEIROS, Rodrigo; TAKAHASHI, Tiago; ANJOS, Carlos Henrique dos; SHIMADA, Andrea K.